• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期肝门部胆管癌的多模态治疗策略

Multimodal treatment strategies for advanced hilar cholangiocarcinoma.

作者信息

Weiss Matthew J, Cosgrove David, Herman Joseph M, Rastegar Neda, Kamel Ihab, Pawlik Timothy M

机构信息

Division of Surgical Oncology, Department of Surgery, The Johns Hopkins Hospital, Blalock 688, 600 N. Wolfe Street, Baltimore, MD, 21287, USA.

出版信息

Langenbecks Arch Surg. 2014 Aug;399(6):679-92. doi: 10.1007/s00423-014-1219-1. Epub 2014 Jun 25.

DOI:10.1007/s00423-014-1219-1
PMID:24962146
Abstract

Cholangiocarcinoma (CCA) is the second most common primary malignancy of the liver arising from malignant transformation and growth of biliary ductal epithelium. Approximately 50-70 % of CCAs arise at the hilar plate of the biliary tree, which are termed hilar cholangiocarcinoma (HC). Various staging systems are currently employed to classify HCs and determine resectability. Depending on the pre-operative staging, the mainstays of treatment include surgery, chemotherapy, radiation therapy, and photodynamic therapy. Surgical resection offers the only chance for cure of HC and achieving an R0 resection has demonstrated improved overall survival. However, obtaining longitudinal and radial surgical margins that are free of tumor can be difficult and frequently requires extensive resections, particularly for advanced HCs. Pre-operative interventions may be necessary to prepare patients for major hepatic resections, including endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangiography, and portal vein embolization. Multimodal therapy that combines chemotherapy with external beam radiation, stereotactic body radiation therapy, bile duct brachytherapy, and/or photodynamic therapy are all possible strategies for advanced HC prior to resection. Orthotopic liver transplantation is another therapeutic option that can achieve complete extirpation of locally advanced HC in judiciously selected patients following standardized neoadjuvant protocols.

摘要

胆管癌(CCA)是肝脏第二常见的原发性恶性肿瘤,由胆管上皮的恶性转化和生长引起。约50%-70%的CCA发生于胆管树的肝门部,称为肝门部胆管癌(HC)。目前采用多种分期系统对HC进行分类并确定可切除性。根据术前分期,主要治疗方法包括手术、化疗、放疗和光动力疗法。手术切除是治愈HC的唯一机会,实现R0切除已证明可提高总体生存率。然而,获得无肿瘤的纵向和径向手术切缘可能很困难,且通常需要广泛切除,尤其是对于晚期HC。术前干预可能是必要的,以便让患者为大型肝切除术做好准备,包括内镜逆行胰胆管造影、经皮经肝胆管造影和门静脉栓塞。化疗与外照射、立体定向体部放疗、胆管近距离放疗和/或光动力疗法相结合的多模式治疗都是晚期HC切除术前可能的策略。原位肝移植是另一种治疗选择,在遵循标准化新辅助方案的情况下,可在经过审慎选择的患者中实现局部晚期HC的完全切除。

相似文献

1
Multimodal treatment strategies for advanced hilar cholangiocarcinoma.晚期肝门部胆管癌的多模态治疗策略
Langenbecks Arch Surg. 2014 Aug;399(6):679-92. doi: 10.1007/s00423-014-1219-1. Epub 2014 Jun 25.
2
Current therapy of hilar cholangiocarcinoma.肝门部胆管癌的当前治疗方法。
Hepatobiliary Pancreat Dis Int. 2012 Feb;11(1):12-7. doi: 10.1016/s1499-3872(11)60119-7.
3
Management of perihilar cholangiocarcinoma in the era of multimodal therapy.多模态治疗时代肝门部胆管癌的管理。
Expert Rev Gastroenterol Hepatol. 2012 Aug;6(4):481-95. doi: 10.1586/egh.12.20.
4
Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience.新时代肝门部胆管癌的外科治疗: 来自首尔峨山医院的经验。
J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):476-89. doi: 10.1007/s00534-009-0204-5. Epub 2009 Oct 23.
5
Resection of hilar cholangiocarcinoma with left hepatectomy after pre-operative embolization of the proper hepatic artery.术前肝固有动脉栓塞后行左半肝切除术治疗肝门部胆管癌。
HPB (Oxford). 2010 Mar;12(2):147-52. doi: 10.1111/j.1477-2574.2009.00152.x.
6
Multidisciplinary treatment for hilar and intrahepatic cholangiocarcinoma: A review of the general principles.肝门部和肝内胆管癌的多学科治疗:一般原则综述。
Int J Surg. 2020 Oct;82S:77-81. doi: 10.1016/j.ijsu.2020.04.067. Epub 2020 May 4.
7
Advances in diagnosis and treatment of hilar cholangiocarcinoma -- a review.肝门部胆管癌的诊断和治疗进展——综述。
Med Sci Monit. 2013 Aug 7;19:648-56. doi: 10.12659/MSM.889379.
8
Downstaging Locally Advanced Cholangiocarcinoma Pre-Liver Transplantation: A Prospective Pilot Study.肝移植前局部晚期胆管癌降期:一项前瞻性初步研究。
J Surg Res. 2019 Oct;242:23-30. doi: 10.1016/j.jss.2019.04.023. Epub 2019 May 3.
9
Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.225例肝门部胆管癌患者的分期、可切除性及预后
Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9. doi: 10.1097/00000658-200110000-00010.
10
Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation.肝门部及肝内胆管癌的当前外科治疗:肝切除术和原位肝移植的作用
Transplant Proc. 2009 Dec;41(10):4023-35. doi: 10.1016/j.transproceed.2009.11.001.

引用本文的文献

1
Comparing a virtual reality head-mounted display to on-screen three-dimensional visualization and two-dimensional computed tomography data for training in decision making in hepatic surgery: a randomized controlled study.虚拟现实头戴式显示器与屏幕三维可视化和二维计算机断层扫描数据在肝外科决策训练中的比较:一项随机对照研究。
Surg Endosc. 2024 May;38(5):2483-2496. doi: 10.1007/s00464-023-10615-8. Epub 2024 Mar 8.
2
Multi-Disciplinary Care of Hilar Cholangiocarcinoma: Review of Guidelines and Recent Advancements.肝门部胆管癌的多学科治疗:指南综述与最新进展
Cancers (Basel). 2023 Dec 20;16(1):30. doi: 10.3390/cancers16010030.
3

本文引用的文献

1
A perspective on molecular therapy in cholangiocarcinoma: present status and future directions.胆管癌分子治疗的现状与未来方向
Hepat Oncol. 2014 Jan 1;1(1):143-157. doi: 10.2217/hep.13.4.
2
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.二代测序揭示肝内胆管癌靶向治疗的新途径
Oncologist. 2014 Mar;19(3):235-42. doi: 10.1634/theoncologist.2013-0352. Epub 2014 Feb 21.
3
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
Mn-doped Ti-based MOFs for magnetic resonance imaging-guided synergistic microwave thermal and microwave dynamic therapy of liver cancer.
用于磁共振成像引导下肝癌协同微波热疗和微波动态治疗的锰掺杂钛基金属有机框架材料。
Bioact Mater. 2023 Mar 29;27:72-81. doi: 10.1016/j.bioactmat.2023.03.019. eCollection 2023 Sep.
4
Inter- and intrafraction dose variations in robotic stereotactic body radiation therapy (SBRT) for perihilar cholangiocarcinoma in the prospective phase I STRONG trial.前瞻性I期STRONG试验中机器人立体定向体部放疗(SBRT)治疗肝门周围胆管癌时的分次间和分次内剂量变化
Front Oncol. 2023 Mar 8;13:1114737. doi: 10.3389/fonc.2023.1114737. eCollection 2023.
5
Selective biliary occlusion in rodents: description of a new technique.啮齿动物的选择性胆管阻塞:一种新技术的描述。
Innov Surg Sci. 2022 Jun 23;7(1):13-22. doi: 10.1515/iss-2021-0044. eCollection 2022 Mar 1.
6
The Interplay Between Biliary Occlusion and Liver Regeneration: Repeated Regeneration Stimuli Restore Biliary Drainage by Promoting Hepatobiliary Remodeling in a Rat Model.胆道梗阻与肝再生之间的相互作用:在大鼠模型中,反复的再生刺激通过促进肝胆重塑恢复胆汁引流
Front Surg. 2022 Apr 25;9:799669. doi: 10.3389/fsurg.2022.799669. eCollection 2022.
7
Stereotactic Body Radiation Therapy after Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: The STRONG Trial, a Phase I Safety and Feasibility Study.化疗后立体定向体部放射治疗不可切除的肝门周围胆管癌:STRONG试验,一项I期安全性和可行性研究。
Cancers (Basel). 2021 Aug 7;13(16):3991. doi: 10.3390/cancers13163991.
8
Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases.肝脏疾病诊断和管理的三维可视化共识建议。
Hepatol Int. 2020 Jul;14(4):437-453. doi: 10.1007/s12072-020-10052-y. Epub 2020 Jul 7.
9
Does additional resection of a positive microscopic ductal margin benefit patients with perihilar cholangiocarcinoma: A systematic review and meta-analysis.阳性微小胆管切缘的额外切除是否有益于肝门周围胆管癌患者:系统评价和荟萃分析。
PLoS One. 2020 May 7;15(5):e0232590. doi: 10.1371/journal.pone.0232590. eCollection 2020.
10
A simple scoring system to predict early recurrence of Bismuth-Corlette type IV perihilar cholangiocarcinoma.一种预测Bismuth-Corlette IV型肝门部胆管癌早期复发的简易评分系统。
Gastroenterol Rep (Oxf). 2019 Apr 21;7(5):345-353. doi: 10.1093/gastro/goz012. eCollection 2019 Oct.
S0941:一项索拉非尼和厄洛替尼治疗晚期胆囊癌或胆管癌患者的 SWOG Ⅱ期研究。
Br J Cancer. 2014 Feb 18;110(4):882-7. doi: 10.1038/bjc.2013.801. Epub 2014 Jan 14.
4
Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.西妥昔单抗、吉西他滨和顺铂治疗不可切除的胆道癌患者的疗效:一项 2 期研究。
Eur J Cancer. 2013 Dec;49(18):3806-12. doi: 10.1016/j.ejca.2013.07.143. Epub 2013 Sep 2.
5
Staging laparoscopy for hilar cholangiocarcinoma in 100 patients.对 100 例肝门部胆管癌患者行腹腔镜分期。
Langenbecks Arch Surg. 2013 Oct;398(7):983-8. doi: 10.1007/s00423-013-1104-3. Epub 2013 Sep 1.
6
Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review.新辅助治疗用于局部晚期肝门部胆管癌降期:一项系统评价
HPB (Oxford). 2014 Apr;16(4):297-303. doi: 10.1111/hpb.12150. Epub 2013 Aug 26.
7
Principles of surgical resection in hilar cholangiocarcinoma.肝门部胆管癌的手术切除原则。
World J Gastrointest Oncol. 2013 Jul 15;5(7):139-46. doi: 10.4251/wjgo.v5.i7.139.
8
Risk factors and classifications of hilar cholangiocarcinoma.肝门部胆管癌的风险因素和分类。
World J Gastrointest Oncol. 2013 Jul 15;5(7):132-8. doi: 10.4251/wjgo.v5.i7.132.
9
Hilar cholangiocarcinoma.肝门部胆管癌。
World J Gastrointest Oncol. 2013 Jul 15;5(7):113-4. doi: 10.4251/wjgo.v5.i7.113.
10
Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma.系统评价和荟萃分析血管切除在肝门部胆管癌治疗中的作用。
HPB (Oxford). 2013 Jul;15(7):492-503. doi: 10.1111/j.1477-2574.2012.00616.x. Epub 2013 Jan 8.